1615 related articles for article (PubMed ID: 20048187)
1. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
2. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
[TBL] [Abstract][Full Text] [Related]
5. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
9. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
11. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
13. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
14. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
[TBL] [Abstract][Full Text] [Related]
15. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
[TBL] [Abstract][Full Text] [Related]
16. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
[TBL] [Abstract][Full Text] [Related]
17. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
19. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]